纳米封装西罗莫司联合pegadricase治疗未控制痛风的随机安慰剂对照3期试验
DISSOLVE I和II两项双盲安慰剂对照3期试验评估纳米封装西罗莫司联合pegadricase(NASP)治疗未控制痛风。265例患者随机接受高剂量或低剂量NASP或安慰剂每4周一次共6次。第21-24周血清尿酸<6 mg/dL时间≥80%的比例NASP组显著高于安慰剂组,安全性总体可耐受。
要点
- 第21-24周SU达标率:高剂量NASP 51%、低剂量NASP 43%、安慰剂8%,两剂量组vs安慰剂P<0.0001。
- 常见不良事件包括痛风发作、感染和口腔炎,输注反应(1小时内)在NASP治疗患者中不常见(4%)。
- 第1-12周痛风发作比例NASP与安慰剂相似,此后NASP组下降而安慰剂组不变。
核心结论
- NASP治疗使第21-24周完全SU应答的患者比例显著高于安慰剂,且总体耐受良好。
- NASP每4周一次可明显减轻未控制痛风患者的疾病负担。
研究设计与样本
- DISSOLVE I和II为双盲、安慰剂对照3期试验,纳入未控制痛风患者。
- 患者按1:1:1随机接受高剂量NASP、低剂量NASP或安慰剂输注,每4周一次共6次。
- 共265例患者接受高剂量NASP、低剂量NASP或安慰剂。
主要发现
- 第21-24周SU<6 mg/dL时间≥80%的比例:高剂量NASP 51%,低剂量NASP 43%,安慰剂8%(两剂量组vs安慰剂P<0.0001)。
- 常见不良事件:痛风发作(高剂量NASP 42.5%,低剂量NASP 44.3%,安慰剂43.3%)、感染(23.0%、18.2%、16.7%)、口腔炎(9.2%、3.4%、0%)。
- NASP治疗患者1小时内输注反应不常见(4%)。
- 第1-12周痛风发作比例NASP与安慰剂相似,此后NASP组下降而安慰剂组不变。
关键数值与推荐
- 主要终点为第21-24周期间血清尿酸(SU)<6 mg/dL的时间占比≥80%的患者比例。
- 次要终点包括健康相关生活质量、痛风石消退、压痛关节和痛风发作。
临床怎么用
- NASP每4周一次方案可用于未控制痛风患者,显著提高SU达标率并总体耐受良好。
- 治疗早期痛风发作比例与安慰剂相似,后续NASP组发作减少,临床需关注早期发作管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: DISSOLVE I and II examined the efficacy and safety of nanoencapsulated sirolimus (NAS) plus pegadricase (NASP) in patients with uncontrolled gout (UG). METHODS: In these double-blind, placebo-controlled Phase 3 trials of NASP, patients were randomized 1:1:1 to infusions of high-dose (HD) or low-dose (LD) NAS plus pegadricase (HD NASP, LD NASP, respectively) or placebo, given every 4 weeks for 6 doses. The primary endpoint was proportion of patients with serum urate (SU) < 6 mg/dL for ≥ 80% of the time during Weeks 21-24. Secondary endpoints included health-related quality of life, tophus resolution, tender joints, and gout flares. Safety was also assessed. RESULTS: Overall, 265 patients received HD NASP, LD NASP, or placebo. SU response during weeks 21 to 24 was significantly higher with NASP than with placebo (HD NASP: 51%; LD NASP: 43%; placebo: 8%; P < 0.0001 for both doses vs placebo). Common adverse events included gout flares (HD NASP: 42.5%; LD NASP: 44.3%; placebo: 43.3%), infections (HD NASP: 23.0%; LD NASP: 18.2%; placebo: 16.7%), and stomatitis (HD NASP: 9.2%; LD NASP: 3.4%; placebo: 0%). Infusion reactions within 1 hour were infrequent (4%) in NASP-treated patients. During weeks 1 to 12, the proportion of patients with flares was similar between NASP- and placebo-treated patients; thereafter, it decreased in NASP-treated patients but remained unchanged with those receiving the placebo. CONCLUSION: NASP treatment resulted in a significantly higher proportion of patients with complete SU response during weeks 21 to 24 compared with placebo and was generally well tolerated. NASP, an every-4-week treatment, can markedly alleviate disease burden in patients with UG.
引用
- Baraf HSB, Khanna PP, Petronijevic M, et al. Efficacy and Safety of Nanoencapsulated Sirolimus Plus Pegadricase: Results From the Randomized, Placebo-Controlled Phase 3 Trials. Arthritis Rheumatol. 2026. PMID: 42351343. doi:10.1002/art.70266
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。